📊 TLSIW Key Takeaways
Is TriSalus Life Sciences, Inc. (TLSIW) a Good Investment?
TriSalus demonstrates strong revenue growth (53.4% YoY) and exceptional gross margins (84.6%), indicating market traction for its products. However, the company faces critical fundamental solvency challenges: negative stockholders equity (-$33.9M), severe operating losses (-$26.9M), and negative operating cash flow (-$18.0M) create an unsustainable financial position. With limited cash runway of approximately 12-13 months at current burn rates, the company's viability depends on dramatic operational improvement or immediate capital infusion.
TriSalus Life Sciences, Inc. Key Strengths (TLSIW)
- Strong YoY revenue growth of 53.4% demonstrates market demand and product adoption
- Exceptional gross margin of 84.6% indicates superior product quality and pricing power
- Adequate short-term liquidity with current ratio of 2.80x provides near-term operational flexibility
TLSIW Stock Risks: TriSalus Life Sciences, Inc. Investment Risks
- Negative stockholders equity of -$33.9M represents technical insolvency with liabilities exceeding assets by $33.9M
- Severe cash burn with -$18.9M free cash flow annually against only $20.4M cash position creates existential runway risk
- Unprofitable operations with -$59.7% operating margin and -30.6x interest coverage indicate fundamentally unsustainable business model at current scale
Key Metrics to Watch
- Operating cash flow inflection point and path to positive FCF
- Operating margin improvement trajectory and cost structure optimization
- Cash depletion rate relative to potential capital raises or revenue acceleration
- Gross margin sustainability as company scales operations
TriSalus Life Sciences, Inc. (TLSIW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.80x current ratio provides a solid financial cushion.
TLSIW Profit Margin, ROE & Profitability Analysis
TLSIW vs Healthcare Sector: How TriSalus Life Sciences, Inc. Compares
How TriSalus Life Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is TriSalus Life Sciences, Inc. Stock Overvalued? TLSIW Valuation Analysis 2026
Based on fundamental analysis, TriSalus Life Sciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
TriSalus Life Sciences, Inc. Balance Sheet: TLSIW Debt, Cash & Liquidity
TLSIW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: TriSalus Life Sciences, Inc.'s revenue has grown significantly by 144% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.31 indicates the company is currently unprofitable.
TLSIW Revenue Growth, EPS Growth & YoY Performance
TLSIW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.9M | $1.5M | $0.03 |
| Q3 2025 | $7.3M | -$2.4M | $-0.12 |
| Q2 2025 | $7.4M | -$4.3M | $-0.21 |
| Q1 2025 | $6.5M | -$10.4M | $-0.39 |
| Q3 2024 | $5.2M | -$1.4M | $-0.12 |
| Q2 2024 | $4.6M | -$4.3M | $-0.21 |
| Q1 2024 | $3.0M | -$8.3M | $-0.57 |
| Q3 2023 | $3.9M | -$1.3M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
TriSalus Life Sciences, Inc. Dividends, Buybacks & Capital Allocation
TLSIW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for TriSalus Life Sciences, Inc. (CIK: 0001826667)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 19, 2026 | 4 | xslF345X06/wk-form4_1779221287.xml | View → |
| May 18, 2026 | 4 | xslF345X06/wk-form4_1779136958.xml | View → |
| May 18, 2026 | 4 | xslF345X06/wk-form4_1779136952.xml | View → |
| May 18, 2026 | 4 | xslF345X06/wk-form4_1779136946.xml | View → |
| May 18, 2026 | 4 | xslF345X06/wk-form4_1779136942.xml | View → |
❓ Frequently Asked Questions about TLSIW
What is the AI rating for TLSIW?
TriSalus Life Sciences, Inc. (TLSIW) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TLSIW's key strengths?
Claude: Strong YoY revenue growth of 53.4% demonstrates market demand and product adoption. Exceptional gross margin of 84.6% indicates superior product quality and pricing power.
What are the risks of investing in TLSIW?
Claude: Negative stockholders equity of -$33.9M represents technical insolvency with liabilities exceeding assets by $33.9M. Severe cash burn with -$18.9M free cash flow annually against only $20.4M cash position creates existential runway risk.
What is TLSIW's revenue and growth?
TriSalus Life Sciences, Inc. reported revenue of $45.2M.
Does TLSIW pay dividends?
TriSalus Life Sciences, Inc. does not currently pay dividends.
Where can I find TLSIW SEC filings?
Official SEC filings for TriSalus Life Sciences, Inc. (CIK: 0001826667) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TLSIW's EPS?
TriSalus Life Sciences, Inc. has a diluted EPS of $-1.84.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TLSIW's fundamental grade?
Based on our AI fundamental analysis in June 2026, TriSalus Life Sciences, Inc. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TLSIW stock overvalued or undervalued?
Valuation metrics for TLSIW: ROE of N/A (sector avg: 15%), net margin of -86.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TLSIW's AI grade for 2026?
Our dual AI analysis gives TriSalus Life Sciences, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TLSIW's free cash flow?
TriSalus Life Sciences, Inc.'s operating cash flow is $-18.0M, with capital expenditures of $918.0K. FCF margin is -41.9%.
How does TLSIW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -86.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.80 (avg: 2).